Ankylosing Spondylitis Market Size to Reach USD $10.5 Billion, Globally, By 2030 at CAGR of 8.2 % – IndustryARC
Due to the high disease frequency in the United States and Canada and the commercial sales of branded drugs, North America was the largest geographical region in 2020 and accounted for over 62% of the overall share.
Ankylosing Spondylitis Market size is forecast to reach $ 10.5 Billion by 2030, growing at a CAGR of 8.2 % during the forecast period 2023-2030. During the forecast period, it is anticipated that advancements in automation for bullet loading, Ankylosing Spondylitis (AS) is a type of inflammatory arthritis that primarily affects the spine and sacroiliac joints. It can also affect other joints in the body, such as the hips, shoulders, and knees. AS is a chronic condition that can lead to stiffness and limited mobility in the affected joints. A study that appeared in Oxford University Press estimated that there were 1.4 to 1.6 million cases in Europe and 4.7 to 5 million cases in the Asia Pacific.
Ankylosing Spondylitis Market Current and Future Trends
Increasing incidences of AS: AS is a chronic inflammatory disease that affects the spine and joints. The incidence of AS is estimated to be around 0.5% to 1% of the global population. The disease is more common in men than women, and it is often diagnosed in young adults. The increasing prevalence of AS is a major driver of market growth.
Rising awareness about AS: There is a growing awareness about AS among patients and healthcare professionals. This is leading to early diagnosis and treatment of the disease, which is in turn driving the growth of the Ankylosing Spondylitis market.
Availability of effective treatment options: There are a number of effective treatment options available for AS, including non-steroidal anti-inflammatory drugs (NSAIDs), biologics, and physical therapy. The availability of these effective treatment options is also driving the growth of the Ankylosing Spondylitis market.
Increasing focus on biologics: Biologics are a class of drugs that target specific molecules involved in the immune system. They are considered to be more effective than traditional treatment options such as NSAIDs. The increasing focus on biologics is expected to drive the growth of the Ankylosing Spondylitis market in the coming years.
Development of new treatment options: There are a number of new treatment options for AS in the pipeline. These include gene therapy, cell therapy, and small molecule drugs. The development of these new treatment options is expected to further drive the growth of the Ankylosing Spondylitis market in the coming years.
Telemedicine and Digital Health: The COVID-19 pandemic accelerated the adoption of telemedicine. This trend is likely to continue, offering AS patients more convenient access to healthcare, including consultations with specialists and monitoring of their condition.The ankylosing spondylitis market is projected to be dominated by the medication segment.
Geographic expansion: The Ankylosing Spondylitis market is expanding to new regions, such as Asia Pacific and Latin America. This is due to the increasing awareness about AS in these regions, and the growing availability of effective treatment options.
Browse Table of Contents of the Full report :
https://www.industryarc.com/Research/ankylosing-spondylitis-market-research-800016
Ankylosing Spondylitis Market Report – Scope:
The Ankylosing Spondylitis Market has been segmented By Drug Class, distribution channels, Disease Stage and geography. The report provides insights into the market dynamics, including market drivers and challenges.
Ankylosing Spondylitis Market with top country data and analysis. The report also highlights the market potential, growth rates, and alternative relevant statistics.
The competitive landscape section features company profiles of major players such as Sanofi, Eli Lilly and Pfizer. This report is a valuable source of guidance and direction for companies and individuals interested in the ankylosing spondylitis market.
Request a sample for the report:
https://www.industryarc.com/pdfdownload.php?id=800016
The top 10 players in the Ankylosing Spondylitis industry are:
- Pfizer
- Eli Lilly
- Sanofi
- AstraZeneca
- Biogen Idec
- Boehringer Ingelheim
- Teva Pharmaceutical
- Bayer
- Roche
- Takeda Pharmaceuticals
Follow the Link to Buy the latest Market Study on Ankylosing Spondylitis :
https://www.industryarc.com/purchasereport.php?id=800016
Browse More Trending Reports related to Ankylosing Spondylitis Industry By IndustryARC :
- Musculoskeletal Diseases Market Size is estimated to reach $7.9 billion by 2027.
- The Diclofenac Market size is set to reach $6.1 billion by 2027.
Why Choose IndustryARC?
IndustryARC is one of the leading market research and consulting firms in the world. It produces over 500 unique market reports annually. If you are looking for a detailed overview of a particular market, you can simply connect with the team at IndustryARC. You can not only buy your preferred market report from the website, but also get personalized assistance on specific reports.
Contact Us:
Mr. Venkat Reddy
IndustryARC
Email: [email protected]
USA: (+1) 518-282-4727
Visit us on social media:
Facebook
Twitter
LinkedIn
Contact Information:
Contact Us: Mr. Venkat Reddy IndustryARC Email: [email protected] USA: (+1) 518-282-4727
Tags:
Extended Distribution, iCN Internal Distribution, BNN, Research Newswire, English